Sort   by:  
 Page size 
UnknownCervical cancer - times… they are a changing: A report from the Society of Gynecologic Oncology journal club.
In January 2021, the Society of Gynecologic Oncology (SGO) Clinical Practice and Education Committees launched a "Journal Club" webinar series to invite national experts to discuss literature pertaining to common clinical scenarios encountered by the members of SGO. On December 13, 2021, SGO hosted ...
S-EPMC8961167 | biostudies-literature
TranscriptomicsExpression data in human renal cell carcinoma samples from patients who did or did not respond to anti-PD-1 (Nivolumab) immunotherapy
Pre-treatment tumor expression of PD-L1 has been shown to correlate with favorable clinical outcomes following PD-1 blocking therapies. However, the majority of patients with PD-L1+ tumors do not respond to treatment. With the goal of obtaining insights into the mechanisms underlying the response to...
ORGANISM(S): Homo sapiens 
2016-08-04 | E-GEOD-67501 | biostudies-arrayexpress
UnknownDiabetes: Concepts of β-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention.
As the world endures a viral pandemic superimposed on a diabetes pandemic, the latter incorporates most of the comorbidities associated with the former, thereby exacerbating risk of death in both. An essential approach to both pandemics is prevention and unrealized earlier treatment. Thus, in this P...
S-EPMC8564410 | biostudies-literature
UnknownPhysiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study.

Purpose

Frailty, a phenotype reported among 9.9% of individuals 65 years old and older (9.6% of women; 5.2% of men), has not been assessed among adult childhood cancer survivors (CCS). We estimated the prevalence of frailty and examined associations with morbidity and mortality.

Methods

S-EPMC3871511 | biostudies-literature
UnknownAdvancing patient-centered research practices in a pragmatic patient-level randomized clinical trial: A thematic analysis of stakeholder engagement in Emergency Medicine Palliative Care Access (EMPallA).

Background

Involving patient and community stakeholders in clinical trials adds value by ensuring research prioritizes patient goals both in conduct of the study and application of the research. The use of stakeholder committees and their impact on the conduct of a multicenter clinical trial...
S-EPMC10807180 | biostudies-literature
UnknownIndividual prediction of heart failure among childhood cancer survivors.

Purpose

To create clinically useful models that incorporate readily available demographic and cancer treatment characteristics to predict individual risk of heart failure among 5-year survivors of childhood cancer.

Patients and methods

Survivors in the Childhood Cancer Survivor Study ...
S-EPMC4314592 | biostudies-literature
UnknownAbsolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer.

Purpose

We developed three absolute risk models for second primary thyroid cancer to assist with long-term clinical monitoring of childhood cancer survivors.

Patients and methods

We used data from the Childhood Cancer Survivor Study (CCSS) and two nested case-control studies (Nordic C...
S-EPMC3530689 | biostudies-literature
UnknownPhase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Purpose

BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant me...
S-EPMC4878037 | biostudies-literature
UnknownHyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.

Purpose

The strong dose-dependent association between anthracyclines and cardiomyopathy is further exacerbated by the co-occurrence of cardiovascular risk factors (diabetes and hypertension). The high morbidity associated with cardiomyopathy necessitates an understanding of the underlying pa...
S-EPMC3927733 | biostudies-literature
UnknownEstrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Purpose

Several mechanisms have been proposed to explain tamoxifen resistance of estrogen receptor (ER) -positive tumors, but a clinically useful explanation for such resistance has not been described. Because the ER is the treatment target for tamoxifen, a linear association between ER expr...
S-EPMC3208536 | biostudies-literature
Sort   by:  
 Page size